التفاصيل البيبلوغرافية
| العنوان: |
Use of intravenous immunoglobulins in clinical practice: data from three French university hospitals. |
| المؤلفون: |
Frauger, Elisabeth, Grassi, Jerome, Pradel, Vincent, Bornet, Charleric, Rouby, Frank, Delorme, Jean, Ousset, Sebastien, Braguer, Diane, Azulay, Jean-Philippe, Penot-Ragon, Christine, Harle, Jean-Robert, Bongrand, Marie-Claude, Weiller, Pierre-Jean, Pouget, Jean, Michel, Gérard, Micallef, Joelle, Reynier, Jean-Pierre, Tardieu, Sophie, Vanelle, Patrice, Blin, Olivier |
| المصدر: |
Fundamental & Clinical Pharmacology; Dec2011, Vol. 25 Issue 6, p753-761, 9p, 3 Charts, 3 Graphs |
| مصطلحات موضوعية: |
IMMUNOGLOBULINS, UNIVERSITY hospitals, NEUROPATHY, DERMATOMYOSITIS |
| مصطلحات جغرافية: |
MARSEILLE (France), FRANCE |
| مستخلص: |
Since several years, the use of intravenous immunoglobulins (IVIg) has increased. This growth has encouraged some countries to publish guidelines. In parallel, some countries have conducted audits to know how IVIg are used in clinical practice in the light of the available guidelines. The objective of this study was to assess IVIg use in three French university hospitals in 2006. All IVIg administrations were evaluated during 6 months (12 September 2005-12 March 2006) in French university hospitals of Marseille. Different data were recorded for each administration: patient characteristics, indication, formulation and quantity. During the study period, 2802 administrations of IVIg (corresponding to a total quantity of 76 780 g) have been recorded. Four hundred and thirty-five patients received at least one of these administrations. The five most reported indications were multifocal motor neuropathy (11.0% of total quantity), chronic inflammatory demyelinating polyradiculoneuropathy (10.2%), corticoresistant dermatomyositis (10.2%), immune thrombocytopaenia (9.9%) and primary immune deficiency (9.1%). According to available French recommendations, 70% of the IVIg use was for 'acknowledged indications', 9% for 'indications to be assessed' and 18% for 'unwarranted indications'. The 10 most reported indications were 'acknowledged indications' according to available recommendations of the French expert group. Nevertheless, the two most reported indications were not approved by the French Health Products Agency (AFSSAPS) at the time of the study and were approved since. [ABSTRACT FROM AUTHOR] |
|
Copyright of Fundamental & Clinical Pharmacology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
